Loss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy
CNS Neuroscience & Therapeutics · 2026-07 · 32 (7)
DOI: 10.1002/cns.71013 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 07.07.2026. Verfasst von Zou Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Developmental Disabilities, Epilepsy, ATPases Associated with Diverse Cellular Activities. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, China Association Against Epilepsy.
Abstract (Originalsprache)
Aim
To delineate the clinical features of AFG3L2 ‐related developmental and epileptic encephalopathy (DEE) and explore its pathogenic mechanisms.
Methods
Whole‐genome and blood transcriptome sequencing were performed in undiagnosed DEE patients. Patient‐derived skin fibroblasts were established for the analysis of RNA and protein expression as well as for mitochondrial functional assays, including OPA1 processing, mtDNA copy number, membrane potential, ATP production, mitochondrial morphology analysis, and mitochondrial stress testing. Additionally, published AFG3L2 ‐related epilepsy cases were systematically reviewed.
Results
We identified four novel AFG3L2 variants in four DEE patients from two unrelated families, including splice‐site/intronic variants in one family and exon‐deletion/intronic variants in the other, fitting a recessive model of disease. In these patients, plus six additional previously reported DEE patients, symptoms included severe developmental delay, intractable seizures, microcephaly, generalized spasticity, and progressive cerebral atrophy. Transcriptome and fibroblast functional analyses revealed aberrant splicing, reduced AFG3L2 expression, defective OPA1 processing, decreased mtDNA content, impaired membrane potential and ATP production, fragmented mitochondrial networks, and diminished respiratory capacity, supporting a loss‐of‐function mechanism. Compared with spastic ataxia 5—usually involving null‐missense or missense‐missense genotypes—DEE predominantly features null‐null combinations. Significance We implicate AFG3L2 as a novel causative gene for DEE, likely through mitochondrial proteostasis failure and bioenergetic compromise, expanding the phenotypic and genotypic spectrum of AFG3L2 ‐related disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Xiangya Hospital of Central South University, Changsha, China.
- Clinical Research Center for Children's Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital of Central South University, Changsha, China.
- NHC Key Laboratory of Human Stem Cell and Reproduction Engineering, Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
Förderung
- Natural Science Foundation of Hunan Province
- China Association Against Epilepsy
Zitieren
APA
Pan, Z., Yang, L., Tang, H., Chen, C., Yang, Q., Wu, T., He, F., Zhang, Z., Liu, F., & Peng, J. (2026). Loss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy. CNS Neuroscience & Therapeutics, 32(7). https://doi.org/10.1002/cns.71013
Vancouver
Pan Z, Yang L, Tang H, Chen C, Yang Q, Wu T, et al. Loss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy. CNS Neuroscience & Therapeutics. 2026;32(7). doi:10.1002/cns.71013
BibTeX
@article{Pan2026,
author = {Pan, Zou and Yang, Li and Tang, Haiyan and Chen, Chen and Yang, Qian and Wu, Tenghui and He, Fang and Zhang, Zhanwei and Liu, Fangyun and Peng, Jing},
title = {Loss of Function of AFG3L2 Leading to Developmental and Epileptic Encephalopathy},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {7},
doi = {10.1002/cns.71013}
}
EUVIMED